Haemostatic management of cardiac surgical haemorrhage

Anaesthesia

Volumn 70, Issue S1, 2015, Pages

  Besser, M W ^a   Ortmann, E ^a,b   Klein, A A ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b KERCKHOFF HEART CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ARGIPRESSIN[1 DEAMINO]; BLOOD CLOTTING FACTOR 7A; FIBRINOGEN;

BLOOD CLOTTING TEST; BLOOD LOSS, SURGICAL; CARDIOPULMONARY BYPASS; HEART SURGERY; HUMAN; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY;

ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION TESTS; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DEAMINO ARGININE VASOPRESSIN; FACTOR VIIA; FIBRINOGEN; HUMANS; PLATELET TRANSFUSION; THROMBELASTOGRAPHY;

EID: 84925222550     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/ANAE.12898     Document Type: Review

References (78)

1. Despotis G, Avidan M, Eby C. Prediction and management of bleeding in cardiac surgery. Journal of Thrombosis and Hae-mostasis 2009; 7(Suppl 1): 111–7.
2. Hung M, Besser M, Sharples LD, Nair SK, Klein AA. The prevalence and association with transfusion, intensive care unit stay and mortality of pre-operative anaemia in a cohort of cardiac surgery patients. Anaesthesia 2011; 66: 812–8.
3. Bennett-Guerrero E, Zhao Y, O’Brien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. Journal of the American Medical Association 2010; 304: 1568–75.
4. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesthesia and Analgesia 1999; 88: 312–9.
5. Gorlinger K, Shore-Lesserson L, Dirkmann D, Hanke AA, Rahe-Meyer N, Tanaka KA. Management of hemorrhage in cardiothoracic surgery. Journal of Cardiothoracic and Vascular Anesthesia 2013; 27: S20–34.
6. Barnard J, Millner R. A review of topical hemostatic agents for use in cardiac surgery. The Annals of Thoracic Surgery 2009; 88: 1377–83.
7. Stammers A, Trowbridge CC. Principles of oxygenator function: gas exchange, heat transfer and operation. In: Gravlee GP, Davis RF, Stammers AH, Ungerleider RM, eds. Cardiopulmonary Bypass: Principles and Practice. Philadelphia, PA: Wolters Kluwer, Lippincott Wiliiams & Wilkins, 2008: 47–63.
8. De Somer F, Van Noten G. Blood pumps in cardiopulmonary bypass. In: Gravlee GP, Davis RF, Stammers AH, Ungerleider RM, eds. Cardiopulmonary Bypass: Principles and Practice. Philadelphia, PA: Wolters Kluwer, Lippincott Wiliiams & Wil-kins, 2008: 35–46.
9. Besser MW, Klein AA. The coagulopathy of cardiopulmonary bypass. Critical Reviews in Clinical Laboratory Sciences 2010; 47: 197–212.
10. Ranucci M, Isgro G, Cazzaniga A, Soro G, Menicanti L, Frigiola A. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999; 14: 437–42.
11. Ranucci M, Isgro G, Cazzaniga A, et al. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002; 17: 199–204.
12. Despotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E, Lap-pas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesthesia and Analgesia 1996; 82: 13–21.
13. Holzheimer RG, Gorlach H, Wilkert S, Hehrlein F, Molloy RG. RG IL-6 and TNFα release in association with neutrophil activation after cardiopulmonary bypass surgery. Infection 1994; 22: 37–42.
14. Horrow JC, Fitch JCK. Management of coagulopathy associated with cardiopulmonary bypass. In: Gravlee GP, Davis RF, Kurusz CCP, Utley JR, eds. Cardiopulmonary Bypass: Principles and Practice. Philadelphia, PA: Lippincott, Williams & Wilkins, 2000: 459–72.
15. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, van Rensburg A, Beattie WS. The influence of baseline hemoglobin concentration on tolerance of anemia in cardiac surgery. Transfusion 2008; 48: 666–72.
16. Vuylsteke A, Pagel C, Gerrard C, et al. The Papworth Bleeding Risk Score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleed- ing. European Journal of Cardiothoracic Surgery 2011; 39: 924–30.
17. Davidson S. State of the art – how I manage coagulopathy in cardiac surgery patients. British Journal of Haematology 2014; 164: 779–89.
18. Weber CF, Gorlinger K, Meininger D, et al. Point-of-care test-ing: a prospective, randomized clinical trial of efficacy in coag-ulopathic cardiac surgery patients. Anesthesiology 2012; 117: 531–47.
19. Rahe-Meyer N, Pichlmaier M, Haverich A, et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. British Journal of Anaesthesia 2009; 102: 785–92.
20. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. European Journal of Anaesthesiology 2013; 30: 270–382.
21. Solomon C, Rahe-Meyer N, Schochl H, Ranucci M, Gorlinger K. Effect of haematocrit on fibrin-based clot firmness in the FIB-TEM test. Blood Transfusion 2013; 11: 412–8.
22. Schlimp CJ, Solomon C, Ranucci M, Hochleitner G, Redl H, Schochl H. The effectiveness of different functional fibrinogen polymerization assays in eliminating platelet contribution to clot strength in thromboelastometry. Anesthesia and Analgesia 2014; 118: 269–76.
23. Agren A, Wikman AT, Ostlund A, Edgren G. TEG functional fibrinogen analysis may overestimate fibrinogen levels. Anesthesia and Analgesia 2014; 118: 933–5.
24. Gorlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased alloge-neic blood transfusion in cardiovascular surgery: a retrospec-tive, single-center cohort study. Anesthesiology 2011; 115: 1179–91.
25. Weber CF, Klages M, Zacharowski K. Perioperative coagulation management during cardiac surgery. Current Opinion in Ana-esthesiology 2013; 26: 60–4.
26. National Institute for Healthcare and Excellence (NICE). Health Technologies Adoption Programme. NICE Diagnostic Support for Viscoelastometric Point-of-Care Testing. 2014. http://guidance. nice.org.uk/htdg13 (accessed 01/09/2014).
27. Orlov D, McCluskey SA, Selby R, Yip P, Pendergrast J, Karko-uti K. Platelet dysfunction as measured by a point-of-care monitor is an independent predictor of high blood loss in cardiac surgery. Anesthesia and Analgesia 2014; 118: 257– 63.
28. Romlin BS, Soderlund F, Wahlander H, Nilsson B, Baghaei F, Je-ppsson A. Platelet count and function in paediatric cardiac surgery: a prospective observational study. British Journal of Anaesthesia 2014; pii: aeu194. [Epub ahead of print]
29. Kong R, Trimmings A, Hutchinson N, et al. Consensus recom-mendations for using the Multiplate for platelet function monitoring before cardiac surgery. International Journal of Laboratory Hematology 2014 July 23; doi: 10.1111/ijlh. 12279. [Epub ahead of print].
30. Schimmer C, Hamouda K, Sommer SP, Ozkur M, Hain J, Leyh R. The predictive value of multiple electrode platelet aggre-gometry (Multiplate) in adult cardiac surgery. The Thoracic and Cardiovascular Surgeon 2013; 61: 733–43.
31. Dekker SE, Viersen VA, Duvekot A, et al. Lysis onset time as diagnostic rotational thromboelastometry parameter for fast detection of hyperfibrinolysis. Anesthesiology 2014; 121: 89– 97.
32. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. Journal of Thrombosis and Haemostasis 2009; 7: 4–13.
33. Raza I, Davenport R, Rourke C, et al. The incidence and mag-nitude of fibrinolytic activation in trauma patients. Journal of Thrombosis and Haemostasis 2013; 11: 307–14.
34. Hornsey P, Krailadsiri S, MacDonald J, et al. Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma. British Journal of Haematology 2000; 109: 665–70.
35. O’Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. British Journal of Haematology 2004; 126: 11–28.
36. Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesthesia and Analgesia 2012; 114: 261–74.
37. Schlimp CJ, Schochl H. The role of fibrinogen in trauma-induced coagulopathy. Hamostaseologie 2014; 34: 29–39.
38. Solomon C, Cadamuro J, Ziegler B, et al. A comparison of fibrinogen measurement methods with fibrin clot elasticity assessed by thromboelastometry, before and after administration of fibrinogen concentrate in cardiac surgery patients. Transfusion 2011; 51: 1695–706.
39. Sorensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. British Journal of Haematology 2010; 149: 834–843.
40. Miller RD. The impact of Vietnam military data on modern civilian transfusion medicine. Anesthesiology 2009; 110: 1412–6.
41. Lal DS, Shaz BH. Massive transfusion: blood component ratios. Current Opinion in Hematology 2013; 20: 521–5.
42. Wang WT, Zhan YH, Hu XB, et al. Fixed rate of blood component improves the survival rate of patients in massive transfusion. Biomedical Sciences Reports 2013; 1: 243–6.
43. Baumann Kreuziger LM, Morton CT, Subramanian AT, Anderson CP, Dries DJ. Not only in trauma patients: hospital-wide implementation of a massive transfusion protocol. Transfusion Medicine 2014; 24: 162–8.
44. Chowdary P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. British Journal of Haematology 2004; 125: 69–73.
45. Stanworth SJ, Walsh TS, Prescott RJ, et al. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. Critical Care 2011; 15: R108.
46. Burns ER, Goldberg SN, Wenz B. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. American Journal of Clinical Pathology 1993; 100: 94–8.
47. Thorell SE, Nash MJ, Thachil J. Clinical implications of clotting screens. International Journal of Laboratory Hematology 2014 March 17; doi 10.1111/ijlh.12206.
48. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospi-tal. Critical Care 2008; 12: R105.
49. Lin DM, Murphy LS, Tran MH. Use of prothrombin complex concentrates and fibrinogen concentrates in the perioperative setting: a systematic review. Transfusion Medicine Reviews 2013; 27: 91–104.
50. Makris M. Optimisation of the prothrombin complex concentrate dose for warfarin reversal. Thrombosis Research 2005; 115: 451–3.
51. Ortmann E, Klein AA, Sharples LD, et al. Point-of-care assessment of hypothermia and protamine-induced platelet dysfunction with multiple electrode aggregometry (Multiplate(R)) in patients undergoing cardiopulmonary bypass. Anesthesia and Analgesia 2013; 116: 533–40.
52. Solomon C, Hartmann J, Osthaus A, et al. Platelet concentrates transfusion in cardiac surgery in relation to preoperative point-of-care assessment of platelet adhesion and aggregation. Platelets 2010; 21: 221–8.
53. Ranucci M, Aronson S, Dietrich W, et al. Patient blood management during cardiac surgery: do we have enough evidence for clinical practice? Journal of Thoracic and Cardiovascular Surgery 2011; 142: e1–32.
54. Hanke AA, Roberg K, Monaca E, et al. Impact of platelet count on results obtained from multiple electrode platelet aggregometry (Multiplate). European Journal of Medical Research 2010; 15: 214–9.
55. Reece MJ, Klein AA, Salviz EA, et al. Near-patient platelet function testing in patients undergoing coronary artery sur-gery: a pilot study. Anaesthesia 2011; 66: 97–103.
56. Gans H, Krivit W. Problems in hemostasis during openheart sur-gery. III. Epsilon amino caproic acid as an inhibitor of plasmino-gen activator activity. Annals of Surgery 1962; 155: 268–76.
57. Ortmann E, Besser MW, Klein AA. Antifibrinolytic agents in current anaesthetic practice. British Journal of Anaesthesia 2013; 111: 549–63.
58. Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioper-ative Ischemia Research Group, Ischemia Reseacrh and Educa-tion Foundation. The risk associated with aprotinin in cardiac surgery. New England Journal of Medicine 2006; 354: 353–65.
59. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. New England Journal of Medicine 2008; 358: 2319–31.
60. Ogawa S, Ohnishi T, Hosokawa K, Szlam F, Chen EP, Tanaka KA. Haemodilution-induced changes in coagulation and effects of haemostatic components under flow conditions. British Journal of Anaesthesia 2013; 111: 1013–23.
61. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. New England Journal of Medicine 1986; 314: 1402– 6.
62. Harker LA. Bleeding after cardiopulmonary bypass. New England Journal of Medicine 1986; 314: 1446–8.
63. Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL. He-mostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991; 84: 2063–70.
64. Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-con-trolled trial in the setting of bleeding after cardiac surgery. Circulation 2009; 120: 21–7.
65. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. New England Journal of Medicine 2010; 363: 1791–800.
66. Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia 2006; 12(Suppl 6): 48–52.
67. Grossmann E, Akyol D, Eder L, et al. Thromboelastometric detection of clotting factor XIII deficiency in cardiac surgery patients. Transfusion Medicine 2013; 23: 407–15.
68. Karkouti K, von Heymann C, Jespersen CM, et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. Journal of Thoracic and Cardiovascular Surgery 2013; 146: 927–39.
69. Levy JH, Gill R, Nussmeier NA, et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-sub-unit homodimer. A preliminary report. Thrombosis and Hae-mostasis 2009; 102: 765–71.
70. Godje O, Gallmeier U, Schelian M, Grunewald M, Mair H. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic and Cardiovascular Surgery 2006; 54: 26–33.
71. Shainoff JR, Estafanous FG, Yared JP, DiBello PM, Kottke-Mar-chant K, Loop FD. Low factor XIIIA levels are associated with increased blood loss after coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery 1994; 108: 437–45.
72. Carlson MA, Calcaterra J, Johanning JM, Pipinos II, Cordes CM, Velander WH. A totally recombinant human fibrin sealant. Journal of Surgery Research 2014; 187: 334–42.
73. Forcillo J, Perrault LP. Armentarium of topical hemostatic products in cardiovascular surgery: an update. Transfusion and Apheresis Science 2014; 50: 26–31.
74. Banninger H, Hardegger T, Tobler A, et al. Fibrin glue in sur-gery: frequent development of inhibitors of bovine thrombin and human factor V. British Journal of Haematology 1993; 85: 528–32.
75. Knobl P, Lechner K. Acquired factor V inhibitors. Bailliere’s Clinical Haematology 1998; 11: 305–18.
76. Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Annals of Thoracic Surgery 2005; 79: 1037–8.
77. Dorion RP, Hamati HF, Landis B, Frey C, Heydt D, Carey D. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Archives of Pathology and Laboratory Medicine 1998; 122: 887–94.
78. Plesca D. A review of topical thrombin. Cleveland Clinic Pharmacotherapy Update 2009; XII: 1–4.